Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5879-5886

  Maity, A ^a   Pore, N ^a   Lee, J ^a   Solomon, D ^a   O'Rourke, D M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN;

ARTICLE; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL HYPOXIA; DOWN-REGULATION; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; LYMPHOKINES; METHIONINE; MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS (GENETICS); RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034667464     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Neoplasms of the central nervous system
2. Robbins Pathologic Basis of Disease, Ed.
3. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy
4. VEGFs, receptors and angiogenesis
5. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
6. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
7. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma
8. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: The key to angiogenesis?
9. The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities
10. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
11. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
12. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
13. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
14. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo
15. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
16. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
17. Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology
18. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms
19. 2 homeostasis
20. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
21. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
22. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification
23. Expression of growth factor receptors in human brain tumours
24. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
25. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
26. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
27. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
28. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
29. Establishing a link between oncogenes and tumor angiogenesis
30. ras oncogenes in human cancer: A review
31. Proliferation of human malignant astrocytomas is dependent on Ras activation
32. 1. Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains
33. 1. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: Implications for subdomain contributions to receptor assembly
34. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
35. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
36. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells
37. Variation in radiation response of mammalian cells as a function of oxygen tension
38. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
39. Construction and identification of cDNA clones for mouse ribosomal proteins: Application for the study of r-protein gene expression
40. Increased stability and transcription both contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia
41. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
42. Gi proteins use a novel βγ- and Ras-independent pathway to activate extracellular signal-regulated kinase and mobilize AP-1 transcription factors in Jurkat T lymphocytes
43. Involvement of phosphoinositide 3-kinase in insulin- or IGF- 1-induced membrane ruffling
44. Tyrosine kinase inhibition: An approach to drug development
45. Epidermal-growth-factor-dependent activation of the src-family kinases
46. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
47. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
48. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes
49. Phosphatidylinositol 3' kinase: One of the effectors of Ras
50. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
51. Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc ε RI-mediated signal transduction
52. Wortmannin, a microbial product inhibitor of myosin light chain kinase
53. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase
54. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction
55. Regulation of the Ras signalling network
56. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
57. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
58. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor
59. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells
60. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia
61. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR
62. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
63. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
64. Sustained mitogen-activated protein kinase activation is induced by transforming erbB receptor complexes
65. Inhibition of EGFR-mediated phosphoinositide-3-OH (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs)
66. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
67. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor receptor gene in fibroblasts
68. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
69. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
70. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase
71. Loss of PTEN facilitates HIF-1 mediated gene expression
72. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics
73. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1
74. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit
75. Regulation of oncogene expression in cultured aortic smooth muscle cells. Post-transcriptional control of c-myc mRNA